Results 71 to 80 of about 5,291,137 (298)

Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review [PDF]

open access: yes, 2008
Background The relevance to coronary heart disease (CHD) of cytokines that govern inflammatory cascades, such as interleukin-6 (IL-6), may be underestimated because such mediators are short acting and prone to fluctuations.
Kaptoge Stephen   +71 more
core   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

open access: yesMolecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park   +6 more
wiley   +1 more source

Neutrophil Gelatinase-Associated Lipocalin and Interleukin-18 in the Prediction of Acute Kidney Injury in Sepsis Patients. [PDF]

open access: yesInt J Gen Med
Yajing Liu,1 Chunming Li,2 Xiaoya Yang,1 Shufen Guo,1 Zhaobo Cui,1 Hongshan Kang,1 Zhen Ma,1 Huiqing Wang1 1Intensive Care Unit, Hengshui People’s Hospital (Harrison International Peace Hospital), Hengshui, 053000, People’s Republic of China; 2Department
Liu Y   +7 more
europepmc   +2 more sources

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

open access: yesMolecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic   +15 more
wiley   +1 more source

Regulation of IL-18 binding protein by IFN-gamma [PDF]

open access: yes, 2003
In this study we investigated the regulation of IL-18BPa by IFN-y in the context of colon cancer and human autoimmune diseases. IL-18BPa is a naturally occuring inhibitor that counteracts IL-18 bioactivity.
Paulukat, Jens
core  

Interleukin-18 Stimulates a Positive Feedback Loop During Renal Obstruction via Interleukin-18 Receptor

open access: yes, 2011
PURPOSE: Interleukin-18 is a proinflammatory cytokine that is an important mediator of obstruction induced renal tubulointerstitial fibrosis independent of tumor necrosis factor-α and β1 activity.
Karen Hile   +11 more
core   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

open access: yesMolecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho   +2 more
wiley   +1 more source

Association of interleukin-18 gene polymorphism with body mass index in women

open access: yesReproductive Biology and Endocrinology, 2012
Background Interleukin (IL)-18 is an important regulator of innate and acquired immune responses and has multiple roles in chronic inflammation and autoimmune disorders. Obesity is characterized by low- grade chronic inflammation.
Kim Hye-Lin   +11 more
doaj   +1 more source

Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist : a Mendelian randomisation analysis [PDF]

open access: yes, 2015
Funded by: UK Medical Research Council, British Heart Foundation, UK National Institute for Health Research, National Institute for Health Research Cambridge Biomedical Research Centre, European Research Council, and European Commission Framework ...
D. F. Easton (7608179)   +874 more
core   +5 more sources

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

open access: yesMolecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy